Pila Pharma AB (publ) held its Annual General Meeting on April 18, 2024 where founder, CEO and Director of the Board with immediate effect has stepped down as the company's CEO. With the purpose of strengthening the market focus and gearing the company as best as possible for growth and to deliver a new development candidate to the industry with a focus on TRPV1, the company is now appointing a new CEO. New CEO of the company is Gustav H. Gram, who until now has held the position as Head of Investor Relations.

Working within the Life Science Industry and in Pila Pharma AB for more than seven years, Gustav H. Gram has a unique insight and extensive experience into Pila Pharma AB. As such he is already primed for this career advancement and can take over the CEO role immediately.